6996 — Antengene Share News
0.000.00%
Last trade - 00:00- HK$1.93bn
- HK$1.39bn
- CNY105.34m
Brief: Antengene Corp Announces Approval Of SNDA By South Korean Ministry Of Food And Drug Safety
Brief: Antengene Corp Says Approval Of NDA By Thailand Food And Drug Administration
Brief: Antengene Corporation Posts H1 Net Income RMB -167 Mln
Brief: Antengene Corp Says Approval Of NDA By Malaysian National Pharmaceutical Regulatory Agency
Brief: Antengene Corp Says John F. Chin Tendered Resignation As Executive Director
Brief: Antengene Says XPOVIO Approved For New Indication In DLBCL In China
Brief: Antengene Says Xpovio Approved For New Indication In Dlbcl- In China By NMPA
Brief: Antengene Corp Posts Full Year Loss Of RMB581.2 Mln
Brief: Antengene Corp Says Selinexor Included In 2023 National Reimbursement Drug List
Brief: Antengene says Collaboration Agreement Between Antengene And Hansoh Pharma
Brief: Antengene Announces New Drug Application Approval For Xpovio®
Brief: Antengene Corp Says U.S. FDA Ind Clearance For Phase I Perform Trial Of ATG-031 In Patients With Advanced Solid Tumors Or B-NHL
Brief: Antengene Corp Says FY Revenue RMB160.1 Mln
Brief: Antengene Corp Says China NMPA Approved Phase I Study Of Atg-022
Over a dozen Chinese-based firms say they have minimal exposure to SVB (updated)
Brief: Antengene Says Group Does Not Hold Cash Deposits Or Lines Of Credit With Silicon Valley Bank
China's Antengene jumps most in 3 months on nod for oncology drug clinical trial
Brief: Antengene Says It Has Entered Into A Global Clinical Collaboration With MSD To Evaluate ATG-037 In Combination With Keytruda
Brief: Antengene Corp Says Kevin Patrick Lynch Resigned From His Office As An Executive Director